Prescription drug care, written for your case.

Prescription drug misuse is defined as using a prescription medication in any way not directed by a doctor, including use without a prescription of your own, use in greater amounts or more often than prescribed, or use for a reason other than the medication was prescribed (NIDA). The pattern moves from misuse to a clinical use disorder when at least two of eleven diagnostic criteria appear in a twelve-month period, including tolerance, withdrawal, cravings, taking more than intended, and continued use despite consequences, with severity rated mild, moderate, or severe. Outpatient care is appropriate across that severity range when the assessment indicates the level of structure that fits.

The three classes of prescription medications most commonly misused are opioid pain relievers, central nervous system depressants including benzodiazepines and sedatives, and prescription stimulants used for attention disorders (NIDA). In 2024, an estimated 7.6 million people in the United States misused prescription opioids in the past year and 4.6 million misused prescription tranquilizers or sedatives, with prescription stimulants making up a smaller but significant share (SAMHSA NSDUH 2024). Treatment is class-specific because the evidence base, the medication options, and the withdrawal profile differ across the three.

Yes, most adults with prescription drug use disorder can be treated effectively in outpatient care when the clinical picture is matched to the right level of care (ASAM Criteria). The Stepwell Center treats prescription drug use disorder across four outpatient levels in Lakeway, Texas: PHP for the most structure, IOP for daily clinical contact while continuing to work, Evening IOP for working adults, and Outpatient for maintenance. Patients whose assessment indicates a need for medically supervised withdrawal, especially from benzodiazepines or higher-dose sedatives, begin with that step before entering outpatient care, and Stepwell coordinates the handoff so the prescribed plan is in place when outpatient begins.

Three medications are FDA-approved for prescription opioid use disorder, buprenorphine, methadone, and extended-release naltrexone, and ongoing medication treatment for opioid use disorder is linked to better retention and outcomes than treatment without medication (FDA). There are currently no FDA-approved medications for benzodiazepine, sedative, or prescription stimulant use disorder, and the evidence base centers on cognitive behavioral therapy, contingency management for stimulants, and medically supervised tapers for benzodiazepines and sedatives (NIDA). At Stepwell, medication selection for any class is informed by your clinical interview, your treatment history, and when indicated, pharmacogenetic testing, so the prescription fits your biology rather than starting on a trial-and-error path.

Benzodiazepine and sedative withdrawal can be medically dangerous when discontinuation is abrupt, with potential complications including seizures, and the standard of care is a gradual, individualized taper under medical supervision rather than sudden discontinuation (NIDA). The taper schedule is personalized to the specific medication, the daily dose, the duration of use, and your overall medical picture, with cognitive behavioral therapy supporting the behavioral side as the dose comes down. At The Stepwell Center, when the assessment indicates a taper is needed, the plan coordinates the medical and behavioral pieces inside one written care plan rather than separating them.

Yes, integrated treatment that addresses prescription drug use disorder and a co-occurring mental health condition in the same plan is the standard of care when both are present, and approximately 21.2 million US adults have both a substance use disorder and a mental illness in the same year (SAMHSA). Prescription opioid use commonly travels with chronic pain and depression, benzodiazepine use commonly travels with anxiety and insomnia, and prescription stimulant misuse commonly travels with attention difficulties and mood symptoms. At Stepwell, integrated dual diagnosis care is built into every plan when both conditions are present, written and delivered by a single care team rather than referred out.

Most commercial PPO and HMO plans cover outpatient prescription drug use disorder treatment as medically necessary behavioral health care, including the four ASAM levels of care offered at Stepwell, under the federal parity protections that apply to mental health and substance use coverage. Specific deductibles, co-insurance, and prior authorization requirements vary by plan and employer, and medications for opioid use disorder are generally covered as a separate pharmacy benefit. Our admissions team verifies benefits before your first appointment, walks through what is covered, and offers private-pay options when coverage falls short. See Insurance and Payment for the current process, or call 512.743.9285.

The Stepwell Center offers same-day or next-day admission to its comprehensive assessment program, with treatment placement following the assessment, typically beginning within a week of your first call. Speed applies to getting you into the assessment, not to skipping it. Your prescribed plan is what determines your starting level of care, the right medication option if MOUD is indicated, the taper plan if a benzodiazepine or sedative is involved, and the modality mix that fits. Call 512.743.9285 or use the contact form to begin.